Tools of the trade to address schooling related communication needs after childhood cancer: A mini-review with consideration of health disparity concerns.

Abstract:

:Over the last 60 years, success rates in treating childhood cancers have grown dramatically from 10% to greater than 85%. Negative effects of treatments, however, place survivors at risk for neurocognitive deficits that can make school challenging. Evidence shows that receiving special education services can benefit affected children. However, communication and knowledge gaps among families and service providers can present access challenges. This mini-review considers the literature on communication between medical providers, families, and school professionals and identifies recommended tools for improving success and efficiency. Additional recommendations are made regarding improving access and adoption of such tools including the need for adaptations and expansions of available resources to address health disparity concerns for an increasingly linguistically and culturally diverse population.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Paré-Blagoev EJ,Ruble K,Jacobson LA

doi

10.1053/j.seminoncol.2020.02.003

subject

Has Abstract

pub_date

2020-02-01 00:00:00

pages

65-72

issue

1

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(20)30003-8

journal_volume

47

pub_type

杂志文章,meta分析,评审
  • Adjuvant therapy for pancreas cancer: advances and controversies.

    abstract::Although the benefit of adjuvant therapy for pancreas cancer is clear, the most effective therapy remains elusive. In the United States, combination therapy with chemotherapy and radiation remains the standard of care, while in other parts of the world the contribution of radiation is questioned. Clinical trials are r...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.05.006

    authors: Mulcahy MF

    更新日期:2007-08-01 00:00:00

  • Anemia and epoetin alfa in high-dose chemotherapy programs for breast cancer patients.

    abstract::Breast cancer patients undergoing therapeutic regimens of high-dose chemotherapy (HDCT) with circulating progenitor cell support often develop anemia. As a general consideration in the transplantation setting, red blood cell transfusions are normally required in patients who have passed the myeloablative phase after H...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.33529

    authors: Danova M,Ferrari S

    更新日期:2002-06-01 00:00:00

  • Cisplatin and platinum analogues in breast cancer.

    abstract::Therapy for metastatic breast cancer can palliate disease and prolong life, but cannot cure. New drugs will be required if this is to change. Cisplatin and its analogue carboplatin offer new approaches to the treatment of metastatic breast cancer. Cisplatin has significant single-agent, front-line activity in metastat...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sledge GW Jr

    更新日期:1992-02-01 00:00:00

  • Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) represents almost three quarters of all cases of lung cancer. Most NSCLC patients present with either locally advanced inoperable disease, stage IV metastatic disease, or comorbid medical conditions that make them unsuitable for curative resection. Among NSCLC patients in the United ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Carney DN

    更新日期:1995-08-01 00:00:00

  • Preclinical experience with docetaxel in gastrointestinal cancers.

    abstract::Docetaxel is a semisynthetic taxane that acts primarily by promoting microtubule assembly and preventing the depolymerization of assembled microtubules, thereby inducing mitotic block and inhibition of cell proliferation. This agent also induces apoptosis and appears to prevent angiogenesis. Although docetaxel has sho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.002

    authors: Bekaii-Saab TS,Villalona-Calero MA

    更新日期:2005-04-01 00:00:00

  • Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.

    abstract::A phase I/II study was conducted to determine the response rate and the toxicity of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin with granulocyte colony-stimulating factor support in patients with untreated advanced head and neck carcinoma. Twenty-eight patients wi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hitt R,Paz-Ares L,Hidalgo M,Colomer R,Brandariz A,Peña M,Alvarez-Vicent J,Hornedo J,Cortés-Funes H

    更新日期:1997-12-01 00:00:00

  • Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.

    abstract::Over 50% of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have stage IV disease at presentation and the most likely organ to be affected by metastases is the liver. Hepatic involvement and hepatic tumor burden is a key prognostic factor affecting survival of these patients and 80% eventually di...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.07.002

    authors: Keutgen XM,Schadde E,Pommier RF,Halfdanarson TR,Howe JR,Kebebew E

    更新日期:2018-08-01 00:00:00

  • Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?

    abstract::A wide variety of cytogenetic abnormalities and molecular pathways have been implicated in the pathogenesis of sarcoma, and significant progress has been made in the past decade toward identifying potential therapeutic targets. However, apart from gastrointestinal stromal tumors (GISTs) and dermatofibrosarcoma protube...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.09.003

    authors: Riedel RF

    更新日期:2011-10-01 00:00:00

  • New perspectives on the toxicity of etoposide.

    abstract::Etoposide has been used in the treatment of a wide variety of neoplasms, including small cell lung cancer. Kaposi's sarcoma, testicular cancer, acute leukemia, and lymphoma. Its current therapeutic use is limited by myelosuppression, particularly neutropenia. Pharmacodynamic studies of etoposide show that this toxicit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kobayashi K,Ratain MJ

    更新日期:1992-12-01 00:00:00

  • Acute promyelocytic leukemia: recent advances in diagnosis and management.

    abstract::Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) characterized by a specific genetic alteration, affecting the retinoic acid receptor-alpha (RARalpha), and leading to a blockage in the differentiation of the granulocytic cells. The accumulation of the promyelocytic blasts in the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2008.04.010

    authors: Lo-Coco F,Ammatuna E,Montesinos P,Sanz MA

    更新日期:2008-08-01 00:00:00

  • Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?

    abstract::Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Saltz L,Janik JE

    更新日期:1997-02-01 00:00:00

  • Radiotherapy-induced salivary dysfunction.

    abstract::Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers. Notably, RT causes irreparable damage to salivary glands that increases the risk for severe and long-term oral and pharyngeal disorders. Several strategies in the treatment of head and neck cancers h...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.12.009

    authors: Ship JA,Hu K

    更新日期:2004-12-01 00:00:00

  • What is a real nomogram?

    abstract::The current resurgence in the use of nomograms as diagnostic and prognostic tools has legitimate roots in their effectiveness in facilitating communication between the doctor and patient. By returning to a more classical approach to nomography, graphical insights can further enlighten the patient beyond what can be ac...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2009.12.003

    authors: Kattan MW,Marasco J

    更新日期:2010-02-01 00:00:00

  • Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.

    abstract::Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. Nucleoside antimetabolites such as fludarabin...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Plunkett W,Gandhi V,Huang P,Robertson LE,Yang LY,Gregoire V,Estey E,Keating MJ

    更新日期:1993-10-01 00:00:00

  • The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.

    abstract::The combination of paclitaxel and carboplatin is now established as the standard first-line chemotherapy regimen for advanced ovarian cancer. Ways in which this standard therapy can be further improved are being investigated, and several approaches have been taken. One approach is to integrate a different cytotoxic ag...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.03.015

    authors: Thigpen T

    更新日期:2006-04-01 00:00:00

  • Simultaneous treatment with single-agent chemotherapy and radiation for locally advanced cancer of the head and neck.

    abstract::A substantial proportion of patients with squamous cell carcinoma of the head and neck have extensive locoregional disease at presentation. While extensive surgical procedures may completely eradicate local disease with acceptable morbidity for smaller tumors, in patients with stage III and IV disease, high local rela...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Eisenberger M,Jacobs M

    更新日期:1992-08-01 00:00:00

  • Taxoids: effective agents in anthracycline-resistant breast cancer.

    abstract::The results of recent clinical trials have shown that docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France), like paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), has high levels of activity in patients with anthracycline-resistant breast cancer. Agents that are at least partially non-cross-resist...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Ravdin PM

    更新日期:1995-12-01 00:00:00

  • Therapy of superficial bladder cancer.

    abstract::Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (Ie, Ta, Tl, and carcinoma in situ [CIS]) with specific objectives that include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression, and prolonging s...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Nseyo UO,Lamm DL

    更新日期:1996-10-01 00:00:00

  • Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

    abstract::The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lym...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/sonc.2003.50062

    authors: Kyle RA,Therneau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,Melton LJ 3rd

    更新日期:2003-04-01 00:00:00

  • Advances in imaging in the postoperative patient with a rising prostate-specific antigen level.

    abstract::Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00359-2

    authors: Hricak H,Schöder H,Pucar D,Lis E,Eberhardt SC,Onyebuchi CN,Scher HI

    更新日期:2003-10-01 00:00:00

  • Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).

    abstract::In studies conducted by the Eastern Cooperative Oncology Group, treatment with either paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) or carboplatin was associated with an improvement in 1-year survival in patients with stage IV non-small cell lung cancer (NSCLC). Based on these findings, a phase II tr...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Johnson DH,Paul DM,Hande KR,DeVore R

    更新日期:1996-12-01 00:00:00

  • Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.

    abstract::The efficacy and toxicity of combination intravenous carboplatin (300 mg/m2) and cyclophosphamide (600 mg/m2) were evaluated in 70 newly diagnosed patients with advanced-stage epithelial ovarian cancer. Cycles were administered at 4-week intervals for a total of six cycles, and treatment was provided on an outpatient ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Teeling M,Hayes Y,Fitzmaurice B,McGing P,Carney DN

    更新日期:1992-02-01 00:00:00

  • Vinorelbine (Navelbine) in the treatment of breast cancer: a summary.

    abstract::One of the new agents intensively studied in the last decade for the treatment of metastatic breast cancer is vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France). This vinca alkaloid produces response rates comparable to other single agents in women with m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Abeloff MD

    更新日期:1995-04-01 00:00:00

  • Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

    abstract::Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor family, which produces factors that are considered to be important mediators of cell growth. Overexpression of HER2, which occurs in approximately 25% to 30% of human breast cancers, has fostered considerable interest i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ewer MS,Gibbs HR,Swafford J,Benjamin RS

    更新日期:1999-08-01 00:00:00

  • Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.

    abstract::In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung ca...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Pisters KM,Kris MG,Bunn PA Jr,Johnson DH,Ruckdeschel JC,Crowley JJ,Ginsberg RJ

    更新日期:1997-08-01 00:00:00

  • Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.

    abstract::Based on the results of several small clinical studies, the experimental data of J. T. Isaacs, and the theoretical considerations about the heterogeneity of prostatic cancer, we investigated the effect of simultaneous hormone-chemotherapy in previously untreated advanced prostatic cancer. Patients (n = 145; 117 stage ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Pummer K

    更新日期:1991-10-01 00:00:00

  • Challenges in the management of stage II colon cancer.

    abstract::Approximately one third of patients diagnosed with early-stage colon cancer will present with lymph node involvement (stage III) and about one quarter with transmural bowel wall invasion but negative lymph nodes (stage II). Adjuvant chemotherapy targets micrometastatic disease to improve disease-free (DFS) and overall...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.05.005

    authors: Dotan E,Cohen SJ

    更新日期:2011-08-01 00:00:00

  • Phase II and III studies with carboplatin in small cell lung cancer.

    abstract::Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC) (11% complete response [CR], 59% CR plus partial response [PR]). Combination carboplatin/etoposide/vincristine (CEV) (phase II trial) led to an overall remission rate of 84% in patients with limited disease (LD), with 52% CRs. The ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Gatzemeier U,Hossfeld DK,Neuhauss R,Reck M,Achterrath W,Lenaz L

    更新日期:1992-02-01 00:00:00

  • The human interferon-alpha species and hybrid proteins.

    abstract::Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Pestka S

    更新日期:1997-06-01 00:00:00

  • The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.

    abstract::Coelomic epithelial carcinoma of the ovary, the most common cause of death from cancer of the female genital tract in the United States, presents most commonly as advanced (stage III or IV) disease. Management consists of aggressive surgical cytoreduction followed by combination chemotherapy, until recently, a platinu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Thigpen T,Vance RB,McGuire WP,Hoskins WJ,Brady M

    更新日期:1995-12-01 00:00:00